Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.

Young, Guy; Escobar, Miguel A; Pipe, Steven W; Cooper, David L

Young, Guy; Escobar, Miguel A; Pipe, Steven W; Cooper, David L.

Afiliação

Young G; Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Escobar MA; University of Texas Health Science Center and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas.
Pipe SW; Hemophilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, Michigan.
Cooper DL; Clinical, Medical and Regulatory Affairs, Novo Nordisk Inc, Plainsboro, New Jersey.

Am J Hematol ; 92(9): 940-945, 2017 Sep.

Article em En | MEDLINE | ID: mdl-28589615

Assuntos

Inibidores dos Fatores de Coagulação Sanguínea/sangue; Fator VIIa/uso terapêutico; Hemofilia A/sangue; Hemofilia A/tratamento farmacológico; Hemorragia/sangue; Hemorragia/prevenção & controle; Humanos; Proteínas Recombinantes/uso terapêutico; Fatores de Risco; Automedicação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator VIIa / Inibidores dos Fatores de Coagulação Sanguínea / Hemofilia A / Hemorragia Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google